An interdisciplinary research team from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), the InnoHK Laboratory of Data Discovery for Health (InnoHK D24H), and the London School of Hygiene & Tropical Medicine (LSHTM) has unveiled the world’s first artificial intelligence (AI) model designed to classify both the cancer stage and risk category of thyroid cancer, achieving impressive accuracy exceeding 90%. This innovative HKUMed AI model promises to significantly cut frontline clinicians’ pre-consultation preparation time by approximately 50%, aligning with the HKSAR Government’s initiative to harness AI technology in healthcare. The findings were published in the journal npj Digital Medicine.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new study led by City of Hope researchers.

A new bone marrow imaging technique could change treatment for cancer, autoimmune disease and musculoskeletal disorders. 

Unique immune cell structures in tumors can boost immunotherapy effects and enhance survival for patients with high-risk advanced melanoma, but testing is labor-intensive and not yet common. New AI-driven testing methods utilize low-cost and easily accessible technologies. They are designed to expedite testing, which could in turn facilitate physician-patient discussions on potential immunotherapy benefits.